Subscribe Now
Free Sample Issue

Vaxcyte: The XpressCF Platform Enables the Development of Broad-Spectrum Vaccines and Overcomes the Limitations of Traditional Cell-Based Approaches

Vaxcyte (NASDAQ: PCVX) is developing next-generation vaccines to prevent and treat bacterial infections using its novel cell-free protein synthesis platform [XpressCF]. PCVX's technology overcomes the limitations of traditional cell-based vaccine approaches and offers broad-spectrum vaccines. The key value drivers are VAX-31 and VAX-24, pneumococcal conjugate vaccines that protect against invasive pneumococcal disease [IPD]. VAX-31 is in Phase 1/2 trials and is progressing rapidly to Phase 3. The pivotal trials are expected to start in mid-2025. The key takeaway, however, is that with VAX-31, PCVX could secure a best-in-class position in the growing pneumococcal vaccine market.

Vaxcyte develops and creates effective broad-spectrum vaccines
Vaxcyte is a non-revenue biotechnology company developing next-generation vaccines to treat or prevent bacterial infections. PCVX utilizes its cell-free protein synthesis platform [XpressCF]. This platform develops and creates effective broad-spectrum vaccines that can overcome bacterial defenses and elicit a strong immune response. In addition, PCVX's approach produces complex proteins using a cell-free process in which the components are extracted from Escherichia coli bacteria without the need for live cells. This also gives PCVX precise control over protein synthesis under non-physiological conditions. The broad-spectrum vaccines can fight bacteria with advanced defense strategies that evade conventional immunizations. Therefore, PCVX pneumococcal vaccines can target their defenses with an enhanced immune system response, increasing their efficacy.

The pneumococcal vaccines offer better protection than competing products
PCVX's current pipeline includes pneumococcal conjugate vaccines for the prevention of invasive pneumococcal disease. Based on recent clinical trial data, their vaccines offer more comprehensive protection than current alternatives from Pfizer and Merck. The lead product candidates are VAX-31 and VAX-24. VAX-31 is designed to protect against serotypes or strains of pneumococcal disease that affect susceptible populations such as adults over 50 and infants. VAX-31 for adults is in Phase 2, with Phase 3 trials expected in mid-2025. VAX-31 for infants is in the preclinical phase, but the company will initiate Phase 2 in Q1 2025 after IND filing and clearance.

First-in-class pneumococcal protection with FDA approval chances for late 2026
Recently, on September 3, 2024, PCVX presented the results of the Phase 1/2 study of VAX-31 for adults 50 years and older. The study showed the favorable safety profile of VAX-31 with no unexpected or serious side effects. Thus, PCVX appears to have a first-in-class vaccine with VAX-31, and all doses indicate that it is suitable for Phase 3 trials. In addition, PCVX data confirmed its carrier-sparing platform to reduce dependence on carrier proteins and include more serotypes in a single vaccine. Overall, VAX-31 is progressing rapidly to Phase 3 clinical trials. Top-line results are expected in 2026. If all goes smoothly, PCVX could receive FDA approval for a first-in-class, broad-spectrum IPD vaccine in a huge market by the end of 2026 or 2027.

Conclusion: Overall, PCVX is proving to be a promising biotech company. Based on the data currently available, its new generation of pneumococcal vaccines is poised to secure a dominant position in its market. However, patience is still needed as a possible FDA approval for VAX-31 or VAX-24 is still several years away. However, both of these drug candidates would give PCVX a leading position in a multi-billion dollar market.

Want to keep reading?

You can find the entire story in The Trader Times. Get a 4-week trial subscription now and access the entire archive! 

array (
  'ID' => '746',
  'post_date' => '2023-09-15 17:23:38',
  'post_date_gmt' => '2023-09-15 15:23:38',
  'post_content' => '',
  'post_title' => 'Top Stories from The Trader Times',
  'post_type' => 'page',
  'post_excerpt' => '/top-stories/',
  'post_status' => 'publish',
  'post_name' => 'en-top-stories',
  'post_modified' => '2024-10-15 19:25:43',
  'post_modified_gmt' => '2024-10-15 17:25:43',
  'post_parent' => '29',
  'commercial_a' => '',
  'commercial_a_free_sample' => 'Free Sample Issue',
  'commercial_a_label_subscribe' => 'Subscribe Now',
  'commercial_a_text' => 'You can find the entire story in The Trader Times.',
  'commercial_a_text_download' => 'Read the full issue now',
  'commercial_a_text_subscribe' => 'Get a 4-week trial subscription now and access the entire archive!',
  'commercial_a_title' => 'Want to keep reading?',
  'download_label' => 'Read the issue',
  'order_alert' => 'Tip: Try our newspaper today with a 4-week trial subscription!',
  'order_label' => 'Get a trial subscription',
  'seo_description' => '',
  'seo_image' => '',
  'seo_title' => '',
  'link' => '/top-stories/',
)